
Applied Therapeutics APLT
Quarterly report 2025-Q3
added 11-13-2025
Applied Therapeutics Total Current Liabilities 2011-2026 | APLT
Annual Total Current Liabilities Applied Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.2 M | 33.4 M | 26.5 M | 21.2 M | 14.1 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 71.2 M | 14.1 M | 33.3 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
64.3 M | $ 3.54 | -2.48 % | $ 1.06 B | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
ADMA Biologics
ADMA
|
69.5 M | $ 15.85 | -4.2 % | $ 3.78 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 0.82 | -0.79 % | $ 4.47 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
324 M | $ 20.39 | 2.67 % | $ 2.57 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
194 M | $ 75.33 | -1.57 % | $ 1.46 B | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.53 | -6.44 % | $ 390 M | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
18.7 M | - | - | $ 521 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
166 M | $ 34.4 | -3.61 % | $ 3.57 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
31.9 M | $ 7.77 | -7.72 % | $ 33.6 M | ||
|
Axsome Therapeutics
AXSM
|
379 M | $ 162.29 | -1.09 % | $ 8.07 B | ||
|
CorMedix
CRMD
|
11.4 M | $ 6.52 | -8.43 % | $ 332 M | ||
|
Champions Oncology
CSBR
|
23.9 M | $ 5.85 | -2.58 % | $ 79.9 M | ||
|
BridgeBio Pharma
BBIO
|
288 M | $ 64.94 | -2.41 % | $ 12.4 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
8.98 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Denali Therapeutics
DNLI
|
102 M | $ 19.72 | -3.19 % | $ 3.24 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
Edesa Biotech
EDSA
|
1.83 M | $ 3.91 | -8.43 % | $ 12.5 M | ||
|
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | ||
|
BioMarin Pharmaceutical
BMRN
|
759 M | $ 60.59 | 0.26 % | $ 11.6 B | ||
|
Equillium
EQ
|
27.6 M | $ 1.7 | -3.14 % | $ 59 M |